Marquette Asset Management LLC Acquires New Holdings in OraSure Technologies, Inc. $OSUR

Marquette Asset Management LLC bought a new position in OraSure Technologies, Inc. (NASDAQ:OSUR) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 134,656 shares of the medical instruments supplier’s stock, valued at approximately $601,000. Marquette Asset Management LLC owned about 0.20% of OraSure Technologies as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in OSUR. Millennium Management LLC raised its position in shares of OraSure Technologies by 71.1% in the third quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier’s stock valued at $6,781,000 after purchasing an additional 878,151 shares during the period. Geode Capital Management LLC boosted its holdings in shares of OraSure Technologies by 6.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,869,868 shares of the medical instruments supplier’s stock worth $5,611,000 after buying an additional 112,851 shares during the period. Cannell Capital LLC boosted its holdings in shares of OraSure Technologies by 33.7% during the 2nd quarter. Cannell Capital LLC now owns 1,864,989 shares of the medical instruments supplier’s stock worth $5,595,000 after buying an additional 470,536 shares during the period. Kotler Kevin acquired a new position in OraSure Technologies in the 4th quarter valued at $4,359,000. Finally, Bridgeway Capital Management LLC grew its stake in OraSure Technologies by 9.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 1,790,260 shares of the medical instruments supplier’s stock valued at $5,371,000 after buying an additional 154,985 shares during the last quarter. Institutional investors own 93.50% of the company’s stock.

Insider Buying and Selling at OraSure Technologies

In related news, Director Steven Kyle Boyd bought 25,000 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was acquired at an average cost of $2.99 per share, with a total value of $74,750.00. Following the acquisition, the director owned 113,462 shares in the company, valued at approximately $339,251.38. This represents a 28.26% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.70% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Wall Street Zen upgraded shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Monday. Weiss Ratings upgraded shares of OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $3.00.

OraSure Technologies Stock Down 1.2%

NASDAQ:OSUR opened at $4.00 on Tuesday. The firm has a market capitalization of $275.40 million, a PE ratio of -5.80 and a beta of 1.00. OraSure Technologies, Inc. has a 12-month low of $2.08 and a 12-month high of $4.58. The firm has a 50-day moving average price of $4.16 and a 200 day moving average price of $3.44.

OraSure Technologies Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.